WO2007121479A3 - Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions - Google Patents

Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions Download PDF

Info

Publication number
WO2007121479A3
WO2007121479A3 PCT/US2007/066892 US2007066892W WO2007121479A3 WO 2007121479 A3 WO2007121479 A3 WO 2007121479A3 US 2007066892 W US2007066892 W US 2007066892W WO 2007121479 A3 WO2007121479 A3 WO 2007121479A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditions
cardiomyopathy
compositions
methods
barth syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/066892
Other languages
French (fr)
Other versions
WO2007121479A2 (en
Inventor
Tim Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DiObex Inc
Original Assignee
DiObex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DiObex Inc filed Critical DiObex Inc
Priority to AU2007237899A priority Critical patent/AU2007237899A1/en
Priority to CA002649720A priority patent/CA2649720A1/en
Priority to EP07760857A priority patent/EP2012800A2/en
Priority to US12/297,356 priority patent/US20090298848A1/en
Publication of WO2007121479A2 publication Critical patent/WO2007121479A2/en
Publication of WO2007121479A3 publication Critical patent/WO2007121479A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions comprising the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates are useful to increase cardiolipin synthesis and for the treatment of Barth Syndrome, diabetic myopathy, cardiomyopathy associated with aging, mitochondrial disease, and other conditions and disorders where cardiolipin deficiency plays a causative or symptomatic role.
PCT/US2007/066892 2006-04-18 2007-04-18 Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions Ceased WO2007121479A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2007237899A AU2007237899A1 (en) 2006-04-18 2007-04-18 Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
CA002649720A CA2649720A1 (en) 2006-04-18 2007-04-18 Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
EP07760857A EP2012800A2 (en) 2006-04-18 2007-04-18 Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
US12/297,356 US20090298848A1 (en) 2006-04-18 2007-04-18 Methods and Compositions for Treating Barth Syndrome, Cardiomyopathy, Mitochondrial Diseases and Other Conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79330806P 2006-04-18 2006-04-18
US60/793,308 2006-04-18

Publications (2)

Publication Number Publication Date
WO2007121479A2 WO2007121479A2 (en) 2007-10-25
WO2007121479A3 true WO2007121479A3 (en) 2008-08-07

Family

ID=38610464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/066892 Ceased WO2007121479A2 (en) 2006-04-18 2007-04-18 Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions

Country Status (5)

Country Link
US (1) US20090298848A1 (en)
EP (1) EP2012800A2 (en)
AU (1) AU2007237899A1 (en)
CA (1) CA2649720A1 (en)
WO (1) WO2007121479A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5821447B2 (en) * 2011-09-13 2015-11-24 大正製薬株式会社 Fatigue judgment method using cardiolipin
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
KR101665970B1 (en) 2015-01-06 2016-10-13 주식회사이-글벳 Method for Producing Ketoconazole Tablets
WO2018104172A1 (en) 2016-12-06 2018-06-14 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating barth syndrome
CN116392490A (en) * 2021-12-27 2023-07-07 中国科学院广州生物医药与健康研究院 Uses of flunarizine and methods of controlling the number of mitochondria in cells
CN118304310A (en) * 2024-06-07 2024-07-09 首都医科大学附属北京友谊医院 New use of cardiolipin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014447A1 (en) * 1992-12-22 1994-07-07 Sepracor, Inc. Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No relevant documents disclosed *

Also Published As

Publication number Publication date
US20090298848A1 (en) 2009-12-03
CA2649720A1 (en) 2007-10-25
AU2007237899A1 (en) 2007-10-25
EP2012800A2 (en) 2009-01-14
WO2007121479A2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
WO2007104789A3 (en) Amylin derivatives
WO2009042922A3 (en) Peptide-peptidase inhibitor conjugates and methods of making and using same
EA200970090A1 (en) METABOLISM MODULATORS AND TREATMENT OF RELATED DISORDERS
WO2010042163A3 (en) Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2007109354A3 (en) Peptide-peptidase inhibitor conjugates and methods of using same
EA200970088A1 (en) METABOLISM MODULATORS AND TREATMENT OF RELATED DISABILITIES
WO2008033460A3 (en) Treating pain, diabetes, and lipid metabolism disorders
WO2008070692A3 (en) Bicyclic compounds and use as antidiabetics
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
SG196776A1 (en) Quinazolinone, quinolone and related analogs as sirtuin modulators
WO2007127726A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2007124337A8 (en) Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
WO2007133802A3 (en) Pharmaceutical formulations of pimavanserin
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
PL2150530T3 (en) Substituted sulfonamide derivatives
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2007149865A3 (en) Methods and compositions related to inhibition of ceramide synthesis
WO2009065922A3 (en) Organic compounds
WO2010021882A3 (en) Cold menthol receptor antagonists
ECSP066883A (en) USEFUL HETEROARILAMINOPIRAZOL DERIVATIVES FOR THE TREATMENT OF DIABETES
WO2008060448A3 (en) Small molecule pak inhibitors
WO2010011811A3 (en) 3-(phenoxyphenylmethyl)pyrrolidine compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07760857

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2649720

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007237899

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007760857

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007237899

Country of ref document: AU

Date of ref document: 20070418

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12297356

Country of ref document: US